Denali Therapeutics Inc. develops medicines for neurodegenerative diseases, lysosomal storage disorders and other serious diseases using its proprietary TransportVehicle™ platform, which is designed to deliver biotherapeutics across the blood-brain barrier. Company news centers on AVLAYAH™ (tividenofusp alfa-eknm), an FDA-approved enzyme replacement therapy for Hunter syndrome (MPS II), and on pipeline programs that use enzyme, protein, oligonucleotide and antibody transport technologies.
Recurring updates cover clinical and preclinical data for programs in Sanfilippo syndrome type A, Pompe disease, Alzheimer’s disease, frontotemporal dementia and Parkinson’s disease, as well as regulatory decisions, conference presentations, collaboration changes, commercial launch activity and quarterly financial results.
Denali Therapeutics Inc. (NASDAQ: DNLI) reported a net loss of $56.8 million for Q1 2020, compared to $39.0 million in the same quarter last year. Collaboration revenue decreased to $3.6 million, attributed mainly to a $2.9 million decline from Sanofi, offset by a $2.3 million increase from Takeda. Total R&D expenses rose to $51.0 million, influenced by external expenses for key programs and higher personnel costs. General and administrative expenses also increased to $12.6 million. As of March 31, 2020, the company held $596.9 million in cash and marketable securities.